Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan D, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AA, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Mesa RA. Hudgens S, et al. Among authors: foltz l. Value Health. 2024 May;27(5):607-613. doi: 10.1016/j.jval.2024.01.014. Epub 2024 Feb 2. Value Health. 2024. PMID: 38311180 Clinical Trial.
Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Among authors: foltz l. Bone Marrow Transplant. 2024 Feb;59(2):295. doi: 10.1038/s41409-023-02194-y. Bone Marrow Transplant. 2024. PMID: 38279008 Free PMC article. No abstract available.
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Among authors: foltz l. Bone Marrow Transplant. 2024 Feb;59(2):196-202. doi: 10.1038/s41409-023-02146-6. Epub 2023 Nov 8. Bone Marrow Transplant. 2024. PMID: 37938736 Free PMC article.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Mesa RA, et al. Among authors: foltz l. Hemasphere. 2023 Oct 24;7(11):e966. doi: 10.1097/HS9.0000000000000966. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37901848 Free PMC article.
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, El-Galaly TC, Todorov B, Gotlib J. Verstovsek S, et al. Among authors: foltz l. Haematologica. 2023 Oct 1;108(10):2730-2742. doi: 10.3324/haematol.2022.282411. Haematologica. 2023. PMID: 37165840 Free PMC article. Clinical Trial.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Mesa RA, et al. Among authors: foltz l. Cancer Med. 2023 May;12(9):10612-10624. doi: 10.1002/cam4.5799. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021939 Free PMC article. Clinical Trial.
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Cherniawsky H, Friedmann J, Nicolson H, Dehghan N, Stubbins RJ, Foltz LM, Leitch HA, Sreenivasan GM, Ambler KLS, Nevill TJ, McGinnis E, Wilson L, Beck DB, Chen LYC, Marcon KM. Cherniawsky H, et al. Among authors: foltz lm. Eur J Haematol. 2023 Jun;110(6):633-638. doi: 10.1111/ejh.13944. Epub 2023 Feb 22. Eur J Haematol. 2023. PMID: 36788756 Review.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
60 results